BACKGROUND: Type 2 cytokine-related immune responses associated with development of antigen-specific IgE antibodies can contribute to pathology in patients with allergic diseases and to fatal anaphylaxis. However, recent findings in mice indicate that IgE also can enhance defense against honeybee venom. OBJECTIVE: We tested whether IgE antibodies, IgE-dependent effector mechanisms, and a local anaphylactic reaction to an unrelated antigen can enhance defense against Russell viper venom (RVV) and determined whether such responses can be influenced by immunization protocol or mouse strain. METHODS: We compared the resistance of RVV-immunized wild-type, IgE-deficient, and Fcer1a-deficient mice after injection of a potentially lethal dose of RVV. RESULTS: A single prior exposure to RVV enhanced the ability of wild-type mice, but not mice lacking IgE or functional FcεRI, to survive challenge with a potentially lethal amount of RVV. Moreover, IgE-dependent local passive cutaneous anaphylaxis in response to challenge with an antigen not naturally present in RVV significantly enhanced resistance to the venom. Finally, we observed different effects on resistance to RVV or honeybee venom in BALB/c versus C57BL/6 mice that had received a second exposure to that venom before challenge with a high dose of that venom. CONCLUSION: These observations illustrate the potential benefit of IgE-dependent effector mechanisms in acquired host defense against venoms. The extent to which type 2 immune responses against venoms can decrease pathology associated with envenomation seems to be influenced by the type of venom, the frequency of venom exposure, and the genetic background of the host.
BACKGROUND: Type 2 cytokine-related immune responses associated with development of antigen-specific IgE antibodies can contribute to pathology in patients with allergic diseases and to fatal anaphylaxis. However, recent findings in mice indicate that IgE also can enhance defense against honeybee venom. OBJECTIVE: We tested whether IgE antibodies, IgE-dependent effector mechanisms, and a local anaphylactic reaction to an unrelated antigen can enhance defense against Russell viper venom (RVV) and determined whether such responses can be influenced by immunization protocol or mouse strain. METHODS: We compared the resistance of RVV-immunized wild-type, IgE-deficient, and Fcer1a-deficientmice after injection of a potentially lethal dose of RVV. RESULTS: A single prior exposure to RVV enhanced the ability of wild-type mice, but not mice lacking IgE or functional FcεRI, to survive challenge with a potentially lethal amount of RVV. Moreover, IgE-dependent local passive cutaneous anaphylaxis in response to challenge with an antigen not naturally present in RVV significantly enhanced resistance to the venom. Finally, we observed different effects on resistance to RVV or honeybee venom in BALB/c versus C57BL/6 mice that had received a second exposure to that venom before challenge with a high dose of that venom. CONCLUSION: These observations illustrate the potential benefit of IgE-dependent effector mechanisms in acquired host defense against venoms. The extent to which type 2 immune responses against venoms can decrease pathology associated with envenomation seems to be influenced by the type of venom, the frequency of venom exposure, and the genetic background of the host.
Authors: Martin Metz; Adrian M Piliponsky; Ching-Cheng Chen; Verena Lammel; Magnus Abrink; Gunnar Pejler; Mindy Tsai; Stephen J Galli Journal: Science Date: 2006-07-28 Impact factor: 47.728
Authors: Bryan G Fry; Kim Roelants; Donald E Champagne; Holger Scheib; Joel D A Tyndall; Glenn F King; Timo J Nevalainen; Janette A Norman; Richard J Lewis; Raymond S Norton; Camila Renjifo; Ricardo C Rodríguez de la Vega Journal: Annu Rev Genomics Hum Genet Date: 2009 Impact factor: 8.929
Authors: J Bousquet; J M Anto; C Bachert; P J Bousquet; P Colombo; R Crameri; M Daëron; W Fokkens; B Leynaert; C Lahoz; M Maurer; G Passalacqua; R Valenta; M van Hage; R Van Ree Journal: Allergy Date: 2006-06 Impact factor: 13.146
Authors: Martin Metz; Michele A Grimbaldeston; Susumu Nakae; Adrian M Piliponsky; Mindy Tsai; Stephen J Galli Journal: Immunol Rev Date: 2007-06 Impact factor: 12.988
Authors: Adrian M Piliponsky; Ching-Cheng Chen; Michele A Grimbaldeston; Stacy M Burns-Guydish; Jonathan Hardy; Janet Kalesnikoff; Christopher H Contag; Mindy Tsai; Stephen J Galli Journal: Am J Pathol Date: 2009-12-24 Impact factor: 4.307
Authors: Lars A Schneider; Susan M Schlenner; Thorsten B Feyerabend; Markus Wunderlin; Hans-Reimer Rodewald Journal: J Exp Med Date: 2007-10-08 Impact factor: 14.307
Authors: Philipp Starkl; Nicolas Gaudenzio; Thomas Marichal; Laurent L Reber; Riccardo Sibilano; Martin L Watzenboeck; Frédéric Fontaine; André C Mueller; Mindy Tsai; Sylvia Knapp; Stephen J Galli Journal: Allergy Date: 2021-05-06 Impact factor: 14.710
Authors: Philipp Starkl; Martin L Watzenboeck; Lauren M Popov; Sophie Zahalka; Anastasiya Hladik; Karin Lakovits; Mariem Radhouani; Arvand Haschemi; Thomas Marichal; Laurent L Reber; Nicolas Gaudenzio; Riccardo Sibilano; Lukas Stulik; Frédéric Fontaine; André C Mueller; Manuel R Amieva; Stephen J Galli; Sylvia Knapp Journal: Immunity Date: 2020-09-09 Impact factor: 43.474